Category: phthalazine

Ceric, Helena et al. published their research in ARKIVOC (Gainesville, FL, United States) in 2009 | CAS: 18393-54-9

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Pyridazine and phthalazine have quite different spectroscopic properties compared with their isomers, pyrazine and quinoxaline. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Electric Literature of C9H8N2O2

Hydrazinolysis study of phthalimido- and phthalisoimido-penicillin amide derivatives was written by Ceric, Helena;Sindler-Kulyk, Marija. And the article was included in ARKIVOC (Gainesville, FL, United States) in 2009.Electric Literature of C9H8N2O2 This article mentions the following:

New phthalimido-penicillin amide (6-PhtPABn, I) and phthalisoimido-penicillin amide (6-isoPhtPABn, II) were prepared and the susceptibility of their different carbonyl functions toward hydrazine derivatives investigated in order to establish the feasibility of dephthaloylation within penicillin class compounds Hydrazinolysis of I resulted in dephthaloylation and β-lactam ring opening into thiazolidine derivatives, while in the case of II, the desired amino-penicillin amide was isolated in low yield. In the experiment, the researchers used many compounds, for example, 2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9Electric Literature of C9H8N2O2).

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Pyridazine and phthalazine have quite different spectroscopic properties compared with their isomers, pyrazine and quinoxaline. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Electric Literature of C9H8N2O2

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Sato, Shinichi et al. published their research in Yakugaku Zasshi in 2018 | CAS: 18393-54-9

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Although, N-containing heterocyclic compounds are widely distributed in nature, the presence of two adjacent nitrogen atoms in the phthalazine ring makes it rare and not very familiar in isolated extracts from living organisms. As with pyridazines, phthalazines, the other benzopyridazines, were also prepared most frequently through the condensation of hydrazines with carbonyl-containing compounds, typically phthalate derivatives. Recommanded Product: 18393-54-9

Development and application of catalytic tyrosine modification was written by Sato, Shinichi;Tsushima, Michihiko;Nakamura, Kosuke;Nakamura, Hiroyuki. And the article was included in Yakugaku Zasshi in 2018.Recommanded Product: 18393-54-9 This article mentions the following:

The chem. labeling of proteins with synthetic probes is a key technique used in chem. biol., protein-based therapy, and material science. Much of the chem. labeling of native proteins, however, depends on the labeling of lysine and cysteine residues. While those methods have significantly contributed to native protein labeling, alternative methods that can modify different amino acid residues are still required. Herein we report the development of a novel methodol. of tyrosine labeling, inspired by the luminol chemiluminescence reaction. Tyrosine residues are often exposed on a protein surface and are thus expected to be good targets for protein functionalization. In our studies so far, we have found that (1) hemin oxidatively activates luminol derivatives as a catalyst, (2) N-Me luminol derivative specifically forms a covalent bond with a tyrosine residue among the 20 kinds of natural amino acid residues, and (3) the efficiency of tyrosine labeling with N-Me luminol derivative is markedly improved by using horseradish peroxidase (HRP) as a catalyst. We were able to use mol. oxygen as an oxidant under HRP/NADH conditions. By using these methods, the functionalization of purified proteins was carried out. Because N-Me luminol derivative is an excellent protein labeling reagent that responds to the activation of peroxidase, this new method is expected to open doors to such biol. applications as the signal amplification of HRP-conjugated antibodies and the detection of protein association in combination with peroxidase-tag technol. In the experiment, the researchers used many compounds, for example, 2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9Recommanded Product: 18393-54-9).

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Although, N-containing heterocyclic compounds are widely distributed in nature, the presence of two adjacent nitrogen atoms in the phthalazine ring makes it rare and not very familiar in isolated extracts from living organisms. As with pyridazines, phthalazines, the other benzopyridazines, were also prepared most frequently through the condensation of hydrazines with carbonyl-containing compounds, typically phthalate derivatives. Recommanded Product: 18393-54-9

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Angara, Kartik et al. published their research in Neoplasia (New York, NY, United States) in 2018 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives.Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as analgesic, anticonvulsant, antitumor, antiproliferative. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Reference of 212141-54-3

CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma was written by Angara, Kartik;Borin, Thaiz F.;Rashid, Mohammad H.;Lebedyeva, Iryna;Ara, Roxan;Lin, Ping-Chang;Iskander, A. S. M.;Bollag, Roni J.;Achyut, Bhagelu R.;Arbab, Ali S.. And the article was included in Neoplasia (New York, NY, United States) in 2018.Reference of 212141-54-3 This article mentions the following:

BACKGROUND: Glioblastoma (GBM) was shown to relapse faster and displayed therapeutic resistance to antiangiogenic therapies (AATs) through an alternative tumor cell-driven mechanism of neovascularization called vascular mimicry (VM). We identified highly upregulated interleukin 8 (IL-8)-CXCR2 axis in tumor cells in high-grade human glioma and AAT-treated orthotopic GBM tumors. METHODS: Human GBM tissue sections and tissue array were used to ascertain the clin. relevance of CXCR2-pos. tumor cells in the formation of VM. We utilized U251 and U87 human tumor cells to understand VM in an orthotopic GBM model and AAT-mediated enhancement in VM was modeled using vatalanib (anti-VEGFR2) and avastin (anti-VEGF). Later, VM was inhibited by SB225002 (CXCR2 inhibitor) in a preclin. study. RESULTS: Overexpression of IL8 and CXCR2 in human datasets and histol. anal. was identified as a bonafide candidate to validate VM through in vitro and animal model studies. AAT-treated tumors displayed a higher number of CXCR2-pos. GBM-stem cells with endothelial-like phenotypes. Stable knockdown of CXCR2 expression in tumor cells led to decreased tumor growth as well as incomplete VM structures in the animal models. Similar data were obtained following SB225002 treatment. CONCLUSIONS: The present study suggests that tumor cell autonomous IL-8-CXCR2 pathway is instrumental in AAT-mediated resistance and VM formation in GBM. Therefore, CXCR2 can be targeted through SB225002 and can be combined with standard therapies to improve the therapeutic outcomes in clin. trials. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Reference of 212141-54-3).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives.Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as analgesic, anticonvulsant, antitumor, antiproliferative. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Reference of 212141-54-3

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Liu, Shuangmei et al. published their research in Neurochemistry International in 2012 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. Also, Phthalazinesare crucial precursors in the synthesis of many compounds with interesting pharmacological properties like phosphodiesterase inhibitors and blood platelet aggregation inhibitors.Computed Properties of C20H15ClN4

Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats was written by Liu, Shuangmei;Xu, Changshui;Li, Guilin;Liu, Han;Xie, Jinyan;Tu, Guihua;Peng, Haiying;Qiu, Shuyi;Liang, Shangdong. And the article was included in Neurochemistry International in 2012.Computed Properties of C20H15ClN4 This article mentions the following:

Neuropathic pain can arise from a lesion affecting the peripheral nervous system. Selective P2X3 and P2X2/3 receptors’ antagonists effectively reduce neuropathic pain. VEGF inhibitors are effective for pain relief. The present study investigated the effects of Vatalanib (VEGF receptor-2 (VEGFR-2) inhibitor) on the neuropathic pain to address the interaction of VEGFR-2 and P2X2/3 receptor in dorsal root ganglia of chronic constriction injury (CCI) rats. Neuropathic pain symptoms following CCI are similar to most peripheral lesions as assessed by the Neuropathic Pain Symptom Inventory. Sprague-Dawley rats were randomly divided into sham group, CCI group and CCI rats treated with Vatalanib group. Mech. withdrawal threshold and thermal withdrawal latency were measured. Co-expression of VEGFR-2 and P2X2 or P2X3 in L4-6 dorsal root ganglia (DRG) was detected by double-label immunofluorescence. The modulation effect of VEGF on P2X2/3 receptor agonist-activated currents in freshly isolated DRG neurons of rats both of sham and CCI rats was recorded by whole-cell patch-clamp technique. The mech. withdrawal threshold (MWT) and thermal withdrawal latency (TWL) in CCI group were lower than those in sham group (p < 0.05). MWT and TWL in CCI rats treated with Vatalanib group were increased compared with those in CCI group (p < 0.05). VEGFR-2 and P2X2 or P2X3 receptors were co-expressed in the cytoplasm and surface membranes of DRG. The co-expression of VEGFR-2 and P2X2 or P2X3 receptor in CCI group exhibited more intense staining than those in sham group and CCI rats treated with Vatalanib group, resp. VEGF enhanced the amplitude of ATP and α,β-meATP -activated currents of both sham and CCI rats. Increment effects of VEGF on ATP and α,β-meATP -activated currents in CCI rats were higher than those in sham rats. Both ATP (100 μM) and α,β-meATP (10 μM)- activated currents enhanced by VEGF (1 nM) were significantly blocked by Vatalanib (1 μM, an inhibitor of VEGF receptors). The stain values of VEGFR-2, P2X2 and P2X3 protein expression in L4/5 DRG of CCI treated with Vatalanib group were significantly decreased compared with those in CCI group (p < 0.01). Vatalanib can alleviate chronic neuropathic pain by decreasing the activation of VEGF on VEGFR-2 and the pos. interaction between the up-regulated VEGFR-2 and P2X2/3 receptors in the neuropathic pain signaling. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Computed Properties of C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. Also, Phthalazinesare crucial precursors in the synthesis of many compounds with interesting pharmacological properties like phosphodiesterase inhibitors and blood platelet aggregation inhibitors.Computed Properties of C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Chen, Guanhong et al. published their research in Yingyong Huaxue in 2011 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. Phthalazines are popular pharmacophores as they are the core chemical motifs in many commercially available drugs such as Azelastin (antihistamine), Vatalanib (vascular endothelial growth factor receptor (VEGFR) inhibitor), and Hydralazine (antihypertensive agent).Safety of N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine

Synthesis and anti-tumor activity of 1-(4-chloroaniline)-4-(4-pyridylmethyl)-2,3-benzodiazine succinate was written by Chen, Guanhong;Wang, Jianing;Kong, Xue;Liu, Kechun. And the article was included in Yingyong Huaxue in 2011.Safety of N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine This article mentions the following:

1-(4-Chloroaniline)-4-(4-pyridylmethyl)-2,3-benzodiazine succinate I was synthesized by addition, rearrangement, substitution and halogenesis steps with phthalide and 4-pyridinecarbaldehydes as starting reagents. The intermediate and target compound I were characterized by 1H NMR, MS and HPLC. After purification by recrystallization, the compound I (98.1% purity estimated by HPLC) was exptl. used to treat colorectal cancer nude mice. The result shows that this compound obviously restrains the growth of tumors. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Safety of N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. Phthalazines are popular pharmacophores as they are the core chemical motifs in many commercially available drugs such as Azelastin (antihistamine), Vatalanib (vascular endothelial growth factor receptor (VEGFR) inhibitor), and Hydralazine (antihypertensive agent).Safety of N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Rosenthal, Arthur F. et al. published their research in Journal of Organic Chemistry in 1957 | CAS: 18393-54-9

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives.Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as analgesic, anticonvulsant, antitumor, antiproliferative. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.COA of Formula: C9H8N2O2

Cleavage of phthaloylglycine by substituted hydrazines was written by Rosenthal, Arthur F.. And the article was included in Journal of Organic Chemistry in 1957.COA of Formula: C9H8N2O2 This article mentions the following:

Refluxing 1.8 g. 2,5-dichlorophenylhydrazine, 1.03 g. phthaloylglycine (I), and 0.93 g. Bu3N in 5 cc. 95% EtOH 12 hrs. on a steam bath, adding 15 cc. Me2CO, refluxing the mixture another 15 min., evaporating the filtered solution in vacuo, taking up the residue in 15 cc. Et2O, treating the Et2O solution 1 min. with HCl, and evaporating the Et2O give 40% N-(2,5-dichlorophenyl)phthalhydrazide, faintly yellow crystals, m. 204-5°. Refluxing 1.03 g. I, 1.85 g. Bu3N, and MeNHNH2 from 1.44 g. sulfate 20 hrs. in 30 cc. 95% EtOH, evaporating the mixture to 1/3 its volume, adding 40 cc. EtCOMe, refluxing the mixture 15 min., filtering off 346 mg. glycine, evaporating the filtrate, and adding 40 cc. Et2O and 100 cc. C5H12 give 88% N-methylphthalhydrazide, m. 238.5-9.5° (N-acetyl-N’-methylphthalhydrazide, m. 139.5-40.5°). In the experiment, the researchers used many compounds, for example, 2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9COA of Formula: C9H8N2O2).

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives.Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as analgesic, anticonvulsant, antitumor, antiproliferative. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.COA of Formula: C9H8N2O2

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Arena, Claudia et al. published their research in BioMed Research International in 2018 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine and phthalazinone derivatives are important owing to their significant biological activities and pharmacological properties. As with pyridazines, phthalazines, the other benzopyridazines, were also prepared most frequently through the condensation of hydrazines with carbonyl-containing compounds, typically phthalate derivatives. COA of Formula: C20H15ClN4

Stomatitis and VEGFR-tyrosine kinase inhibitors (VR-TKIs): a review of current literature in 4369 patients was written by Arena, Claudia;Troiano, Giuseppe;De Lillo, Alfredo;Testa, Nunzio F.;Lo Muzio, Lorenzo. And the article was included in BioMed Research International in 2018.COA of Formula: C20H15ClN4 This article mentions the following:

Background. Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss of appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppression, and stomatitis. Materials and Methods. A systematic search was performed on PubMed online database using a combination of MESH terms and free text words, “sunitinib” OR “sorafenib” OR “axitinib” OR “cabozantinib” OR “pazopanib” OR “regorafenib” OR “nintedanib” OR “vatalanib” combined through the use of Boolean operator AND with the key words”stomatitis” OR “mucositis,” (i) on human subjects, (ii) written in the English language, and (iii) reporting about the incidence of stomatitis or oral mucositis. Results.. The incidence of stomatitis of any grade was 35.2% for sunitinib, 20.52% for sorafenib, 20.63% for axitinib, and 34.21% for cabozantinib. All the agents showed high rates of lowgrade stomatitis (G1-G2), while the onset of severe stomatitis (G3-G4) was very low. Conclusions. Anal. of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3COA of Formula: C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine and phthalazinone derivatives are important owing to their significant biological activities and pharmacological properties. As with pyridazines, phthalazines, the other benzopyridazines, were also prepared most frequently through the condensation of hydrazines with carbonyl-containing compounds, typically phthalate derivatives. COA of Formula: C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Cheinker, Yu. N. et al. published their research in Journal de Chimie Physique et de Physico-Chimie Biologique in 1958 | CAS: 18393-54-9

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. New methods for the functionalization of pyridazine, phthalazine, and cinnoline rings emerged in 2016. Buchwald and his group devised an asymmetric hydroarylation of vinylarenes.Reference of 18393-54-9

Spectra and structure of derivatives of p-dihydroxypyridazine and phthalazine was written by Cheinker, Yu. N.;Gortinskaya, T. V.;Sycheva, T. P.. And the article was included in Journal de Chimie Physique et de Physico-Chimie Biologique in 1958.Reference of 18393-54-9 This article mentions the following:

IR and UV spectra of the dihydroxy derivatives of pyridazine and phthalazine, as well as their Me and Cl derivatives, were studied with a view to establishing the structure of the dihydroxy derivatives It was concluded that the compounds have mixed hydroxyoxo structures, both in the crystalline state and in solution Mols. of 3-hydroxy-6-pyridazine (I), as well as the 1-Me derivative, form chains in the crystalline state, in which each mol. is linked to 2 others by very stable H bonds. The H-bonds in 1-hydroxy-4-phthalazinone (II) do not lead to such chain formation in the crystalline state. The heats of fusion, solubility, and acidity of I, II, and derivatives are consistent with the proposed structures. IR spectra of the following compounds are given between 20 and 14 μ: 1,2-dimethyl-3,6-pyridazinedione, I, 3,6-dimethoxypyridazine, 1-methyl-3-methoxy-6-pyridazinone, 3-methoxy-6-pyridazinone, 1-methyl-3-hydroxy-6-pyridazinone, 2,3-dimethyl-1,4-phthalazinedione II, 1-methoxy-4-phthalazinone, 1-methoxy-4-chlorophthalazine, 3-chloro-6-pyridazinone, 3,6-dichloropyridazine, 3,6-bis(methylthio)pyridazine, 3-mercapto-6-thiopyridazinone, all in the crystalline state; also UV spectra in alc. In the experiment, the researchers used many compounds, for example, 2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9Reference of 18393-54-9).

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. New methods for the functionalization of pyridazine, phthalazine, and cinnoline rings emerged in 2016. Buchwald and his group devised an asymmetric hydroarylation of vinylarenes.Reference of 18393-54-9

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Li, Yan et al. published their research in Journal of Chemical Information and Modeling in 2016 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Although, N-containing heterocyclic compounds are widely distributed in nature, the presence of two adjacent nitrogen atoms in the phthalazine ring makes it rare and not very familiar in isolated extracts from living organisms. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Synthetic Route of C20H15ClN4

AutoT&T v.2: An Efficient and Versatile Tool for Lead Structure Generation and Optimization was written by Li, Yan;Zhao, Zhixiong;Liu, Zhihai;Su, Minyi;Wang, Renxiao. And the article was included in Journal of Chemical Information and Modeling in 2016.Synthetic Route of C20H15ClN4 This article mentions the following:

In structure-based drug design, automated de novo design methods are helpful tools for lead discovery as well as lead optimization. In a previous study the authors reported a new de novo design method, namely, Automatic Tailoring and Transplanting (AutoT&T). It overcomes some intrinsic problems in conventional fragment-based buildup methods. In this study, the authors describe an upgraded version, namely, AutoT&T2. Structural operations conducted by AutoT&T2 have been largely optimized by introducing several new algorithms. As a result, its overall speed in multiround optimization jobs has been improved by a few thousand fold. With this improvement, it is now practical to conduct structural crossover among multiple lead mols. using AutoT&T2. Three different test cases are described in this study that demonstrate the new features and versatile applications of AutoT&T2. The AutoT&T2 software suite is available to the public. Besides, a Web portal for running AutoT&T2 online is provided at http://www.sioc-ccbg.ac.cn/software/att2 for testing. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Synthetic Route of C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Although, N-containing heterocyclic compounds are widely distributed in nature, the presence of two adjacent nitrogen atoms in the phthalazine ring makes it rare and not very familiar in isolated extracts from living organisms. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Synthetic Route of C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Niimura, Takeshi et al. published their research in Bunshi Shokakibyo in 2012 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as antimicrobial, antidiabetic, analgesic, anticonvulsant, antitumor, antiproliferative, antiepileptic, anti-inflammatory, and vasorelaxant. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Related Products of 212141-54-3

Possibility of new molecular-targeted therapy from the perspective of GIST treatment resistant examples was written by Niimura, Takeshi;Suzuki, Hiromu;Shinomura, Yasuhisa. And the article was included in Bunshi Shokakibyo in 2012.Related Products of 212141-54-3 This article mentions the following:

Imatinib mesilate (imatinib), sunitinib malate (sunitinib) are being used as a drug treatment against Gastrointestinal stromal tumor (GIST) but some cases having resistance against these drugs have also been appeared. Imatinib resistance includes a primary resistance wherein an effect is considered to be less from the beginning and a secondary resistance due to acquisition of new genetic mutation. The mechanism of sunitinib resistance is not completely understood; however, autonomous activation of KIT due to the mutation of activation loop and decrease in the development of PTEN due to the methylation of promoter area and activation of Akt path etc. have been reported. A medical treatment using multi-target Tyrosine kinase such as Nilotinib hydrochloride which is the new tyrosine kinase inhibitor against imatinib, sunitinib resistance cases, inhibitors of intracellular signal transmission path such a mTOR, sorafenib tosilate that targets both of the Tyrosine kinase and intracellular signal transmission mols. is being considered. In addition, the drugs targeting the mols. such as heat shock protein (Hsp) 90 which are involved in the tumor formation are being considered as medical treatment target and clin. trials are also in progress. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Related Products of 212141-54-3).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as antimicrobial, antidiabetic, analgesic, anticonvulsant, antitumor, antiproliferative, antiepileptic, anti-inflammatory, and vasorelaxant. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Related Products of 212141-54-3

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem